Anika Therapeutics Inc.

39.80-0.6800-1.68%Vol 99.18K1Y Perf 21.66%
Apr 9th, 2021 16:00 DELAYED
BID39.80 ASK39.94
Open40.30 Previous Close40.48
Pre-Market- After-Market39.80
 - -  - -%
Target Price
44.00 
Analyst Rating
Moderate Buy 1.67
Potential %
10.55 
Finscreener Ranking
★★★     50.69
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★     51.94
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★+     51.61
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap570.33M 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
61.53 
Earnings Date
6th May 2021

Today's Price Range

39.6140.98

52W Range

27.5347.47

5 Year PE Ratio Range

11.6059.20

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Strong Buy
Performance
1 Week
-1.00%
1 Month
13.45%
3 Months
-7.14%
6 Months
3.86%
1 Year
21.66%
3 Years
-13.96%
5 Years
-11.61%
10 Years
357.47%

TickerPriceChg.Chg.%
ANIK39.80-0.6800-1.68
AAPL132.992.63002.02
GOOG2 285.8820.44000.90
MSFT255.852.60001.03
XOM55.87-0.1300-0.23
WFC40.500.47001.17
JNJ161.25-1.7200-1.06
FB312.46-0.5600-0.18
GE13.600.15001.12
JPM156.281.16000.75
Financial StrengthValueIndustryS&P 500US Markets
3.30
4.80
0.07
0.08
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
52.90
-11.10
-0.80
17.60
-33.32
RevenueValueIndustryS&P 500US Markets
95.06M
6.63
5.75
4.61
Earnings HistoryEstimateReportedSurprise %
Q04 20200.110.129.09
Q03 20200.13-0.45-446.15
Q02 2020-0.210.09142.86
Q01 20200.400.4512.50
Q04 20190.410.434.88
Q03 20190.410.6456.10
Q02 20190.420.6759.52
Q01 20190.210.3147.62
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.01-94.12Negative
6/2021 QR0.03-85.71Negative
12/2021 FY0.19-78.89Negative
12/2022 FY0.53-62.14Negative
Next Report Date6th May 2021
Estimated EPS Next Report0.01
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume99.18K
Shares Outstanding14.33M
Trades Count2.48K
Dollar Volume6.39M
Avg. Volume148.03K
Avg. Weekly Volume138.48K
Avg. Monthly Volume208.01K
Avg. Quarterly Volume149.90K

Anika Therapeutics Inc. (NASDAQ: ANIK) stock closed at 39.8 per share at the end of the most recent trading day (a -1.68% change compared to the prior day closing price) with a volume of 99.20K shares and market capitalization of 570.33M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 154 people. Anika Therapeutics Inc. CEO is Cheryl R. Blanchard.

The one-year performance of Anika Therapeutics Inc. stock is 21.66%, while year-to-date (YTD) performance is -12.06%. ANIK stock has a five-year performance of -11.61%. Its 52-week range is between 27.53 and 47.47, which gives ANIK stock a 52-week price range ratio of 61.53%

Anika Therapeutics Inc. currently has a PE ratio of -23.80, a price-to-book (PB) ratio of 2.15, a price-to-sale (PS) ratio of 6.10, a price to cashflow ratio of 44.40, a PEG ratio of 2.32, a ROA of -6.61%, a ROC of -1.34% and a ROE of -8.18%. The company’s profit margin is -33.32%, its EBITDA margin is -0.80%, and its revenue ttm is $95.06 Million , which makes it $6.63 revenue per share.

Of the last four earnings reports from Anika Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.01 for the next earnings report. Anika Therapeutics Inc.’s next earnings report date is 06th May 2021.

The consensus rating of Wall Street analysts for Anika Therapeutics Inc. is Moderate Buy (1.67), with a target price of $44, which is +10.55% compared to the current price. The earnings rating for Anika Therapeutics Inc. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Anika Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Anika Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.50, ATR14 : 2.22, CCI20 : -173.76, Chaikin Money Flow : -0.26, MACD : -0.92, Money Flow Index : 45.33, ROC : -7.31, RSI : 39.69, STOCH (14,3) : 22.14, STOCH RSI : 0.31, UO : 37.05, Williams %R : -77.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Anika Therapeutics Inc. in the last 12-months were: Cheryl R. Blanchard (Option Excercise at a value of $0), David Colleran (Option Excercise at a value of $0), James Loerop (Option Excercise at a value of $0), James Loerop (Sold 1 244 shares of value $43 727 ), Raymond J. Land (Sold 6 892 shares of value $253 419 ), Thomas Finnerty (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (66.67 %)
2 (66.67 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (33.33 %)
1 (33.33 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.67
Moderate Buy
1.67
Strong Buy
1.00

Anika Therapeutics Inc.

Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company's product profile includes Orthobiologics, Dermal, Surgical and other of which Orthobiologics products generates maximum revenue to the company.

CEO: Cheryl R. Blanchard

Telephone: +1 781 457-9000

Address: 32 Wiggins Avenue, Bedford 01730, MA, US

Number of employees: 154

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

52%48%

Bearish Bullish

58%42%

News

Stocktwits